Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial
dc.contributor.author | McGuire, Darren K. | |
dc.contributor.author | Busui, Rodica P. | |
dc.contributor.author | Deanfield, John | |
dc.contributor.author | Inzucchi, Silvio E. | |
dc.contributor.author | Mann, Johannes F. E. | |
dc.contributor.author | Marx, Nikolaus | |
dc.contributor.author | Mulvagh, Sharon L. | |
dc.contributor.author | Poulter, Neil | |
dc.contributor.author | Engelmann, Mads D. M. | |
dc.contributor.author | Hovingh, G. Kees | |
dc.contributor.author | Ripa, Maria Sejersten | |
dc.contributor.author | Gislum, Mette | |
dc.contributor.author | Brown-Frandsen, Kirstine | |
dc.contributor.author | Buse, John B. | |
dc.date.accessioned | 2023-07-14T13:53:44Z | |
dc.date.available | 2024-08-14 09:53:43 | en |
dc.date.available | 2023-07-14T13:53:44Z | |
dc.date.issued | 2023-07 | |
dc.identifier.citation | McGuire, Darren K.; Busui, Rodica P.; Deanfield, John; Inzucchi, Silvio E.; Mann, Johannes F. E.; Marx, Nikolaus; Mulvagh, Sharon L.; Poulter, Neil; Engelmann, Mads D. M.; Hovingh, G. Kees; Ripa, Maria Sejersten; Gislum, Mette; Brown-Frandsen, Kirstine ; Buse, John B. (2023). "Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial." Diabetes, Obesity and Metabolism 25(7): 1932-1941. | |
dc.identifier.issn | 1462-8902 | |
dc.identifier.issn | 1463-1326 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/177193 | |
dc.description.abstract | AimTo describe the design of the SOUL trial (Semaglutide cardiOvascular oUtcomes triaL) and the baseline clinical data of its participants.Materials and methodsIn SOUL, the effects of oral semaglutide, the first oral glucagon-like peptide-1 receptor agonist, on the risk of cardiovascular (CV) events in individuals with type 2 diabetes and established atherosclerotic CV disease (ASCVD) and/or chronic kidney disease (CKD) will be assessed. SOUL is a randomized, double-blind, parallel-group, placebo-controlled CV outcomes trial comparing oral semaglutide (14 mg once daily) with placebo, both in addition to standard of care, in individuals aged ≥50 years with type 2 diabetes and evidence of ASCVD (coronary artery disease [CAD], cerebrovascular disease, symptomatic peripheral arterial disease [PAD]) and/or CKD (estimated glomerular filtration rate <60 mL/min/1.73 m2). The primary outcome is time from randomization to first occurrence of a major adverse CV event (MACE; a composite of CV death, nonfatal myocardial infarction or nonfatal stroke). This event-driven trial will continue until 1225 first adjudication-confirmed MACEs have occurred. Enrolment has been completed.ResultsOverall, 9650 participants were enrolled between June 17, 2019 and March 24, 2021 (men 71.1%, White ethnicity 68.9%, mean age 66.1 years, diabetes duration 15.4 years, body mass index 31.1 kg/m2, glycated haemoglobin 63.5 mmol/mol [8.0%]). The most frequently used antihyperglycaemic medications at baseline were metformin (75.7%), insulin and insulin analogues (50.5%), sulphonylureas (29.1%), sodium-glucose cotransporter-2 inhibitors (26.7%) and dipeptidyl peptidase-4 inhibitors (23.0%). At randomization, 70.7% of participants had CAD, 42.3% had CKD, 21.1% had cerebrovascular disease and 15.7% had symptomatic PAD (categories not mutually exclusive). Prevalent heart failure was reported in 23.0% of participants.ConclusionSOUL will provide evidence regarding the CV effects of oral semaglutide in individuals with type 2 diabetes and established ASCVD and/or CKD. | |
dc.publisher | Blackwell Publishing Ltd | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.subject.other | randomized trial | |
dc.subject.other | type 2 diabetes | |
dc.subject.other | semaglutide | |
dc.subject.other | GLP-1 | |
dc.subject.other | cardiovascular disease | |
dc.title | Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial | |
dc.type | Article | |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Public Health (General) | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/177193/1/dom15058.pdf | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/177193/2/dom15058_am.pdf | |
dc.identifier.doi | 10.1111/dom.15058 | |
dc.identifier.source | Diabetes, Obesity and Metabolism | |
dc.identifier.citedreference | Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016; 375: 311 - 322. | |
dc.identifier.citedreference | McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol. 2021; 6: 148 - 158. | |
dc.identifier.citedreference | Thethi TK, Pratley R, Meier JJ. Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: the PIONEER programme. Diabetes Obes Metab. 2020; 22: 1263 - 1277. | |
dc.identifier.citedreference | Aroda VR, Ahmann A, Cariou B, et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the SUSTAIN 1-7 trials. Diabetes Metab. 2019; 45: 409 - 418. | |
dc.identifier.citedreference | Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016; 375: 1834 - 1844. | |
dc.identifier.citedreference | Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019; 381: 841 - 851. | |
dc.identifier.citedreference | Hicks KA, Mahaffey KW, Mehran R, et al. 2017 cardiovascular and stroke endpoint definitions for clinical trials. Circulation. 2018; 137: 961 - 972. | |
dc.identifier.citedreference | Novo Nordisk A/S. SAXENDA® Highlights of Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/206321s015lbl.pdf. Accessed September 27, 2022 | |
dc.identifier.citedreference | Eli Lilly and company. TRULICITY® Highlights of Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125469s033lbl.pdf. Accessed September 27, 2022 | |
dc.identifier.citedreference | American Diabetes Association professional practice committee. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2022. Diabetes Care. 2022; 45: S17 - S38. | |
dc.identifier.citedreference | Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150: 604 - 612. | |
dc.identifier.citedreference | Delgado C, Baweja M, Crews DC, et al. A unifying approach for GFR estimation: recommendations of the NKF-ASN task force on reassessing the inclusion of race in diagnosing kidney disease. Am J Kidney Dis. 2022; 79: 268 - 288.e261. | |
dc.identifier.citedreference | Grieco M, Giorgi A, Gentile MC, et al. Glucagon-like peptide-1: a focus on neurodegenerative diseases. Front Neurosci. 2019; 13: 1112. | |
dc.identifier.citedreference | Yaribeygi H, Rashidy-Pour A, Atkin SL, Jamialahmadi T, Sahebkar A. GLP-1 mimetics and cognition. Life Sci. 2021; 264: 118645. | |
dc.identifier.citedreference | Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005; 53: 695 - 699. | |
dc.identifier.citedreference | Brooker H, Wesnes KA, Ballard C, et al. An online investigation of the relationship between the frequency of word puzzle use and cognitive function in a large sample of older adults. Int J Geriatr Psychiatry. 2019; 34: 921 - 931. | |
dc.identifier.citedreference | Brooker H, Wesnes KA, Ballard C, et al. The relationship between the frequency of number-puzzle use and baseline cognitive function in a large online sample of adults aged 50 and over. Int J Geriatr Psychiatry. 2019; 34: 932 - 940. | |
dc.identifier.citedreference | Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019; 394: 121 - 130. | |
dc.identifier.citedreference | Gerstein HC, Sattar N, Rosenstock J, et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med. 2021; 385: 896 - 907. | |
dc.identifier.citedreference | Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (harmony outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018; 392: 1519 - 1529. | |
dc.identifier.citedreference | Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017; 377: 1228 - 1239. | |
dc.identifier.citedreference | Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015; 373: 2247 - 2257. | |
dc.identifier.citedreference | Ruff CT, Baron M, Im K, O’Donoghue ML, Fiedorek FT, Sabatine MS. Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial. Nat Med. 2022; 28: 89 - 95. | |
dc.identifier.citedreference | Andersen A, Knop FK, Vilsbøll T. A pharmacological and clinical overview of oral semaglutide for the treatment of type 2 diabetes. Drugs. 2021; 81: 1003 - 1030. | |
dc.identifier.citedreference | Gallwitz B, Giorgino F. Clinical perspectives on the use of subcutaneous and oral formulations of semaglutide. Front Endocrinol (Lausanne). 2021; 12: 645507. | |
dc.identifier.citedreference | Butler J, Packer M, Greene SJ, et al. Heart failure end points in cardiovascular outcome trials of sodium glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a critical evaluation of clinical and regulatory issues. Circulation. 2019; 140: 2108 - 2118. | |
dc.identifier.citedreference | Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019; 380: 2295 - 2306. | |
dc.identifier.citedreference | Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019; 380: 347 - 357. | |
dc.identifier.citedreference | ClinicalTrials.gov. A Research Study to Look at how Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People with Type 2 Diabetes (FOCUS). https://clinicaltrials.gov/ct2/show/NCT03811561. Accessed 1 February, 2023 | |
dc.identifier.citedreference | ClinicalTrials.gov. Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity (SELECT). https://clinicaltrials.gov/ct2/show/NCT03574597?term=NCT03574597&draw=2&rank=1. Accessed 17 February, 2023 | |
dc.identifier.citedreference | ClinicalTrials.gov. A Research Study to See how Semaglutide Works Compared to Placebo in People with Type 2 Diabetes and Chronic Kidney Disease (FLOW). https://clinicaltrials.gov/ct2/show/NCT03819153?term=NCT03819153&draw=2&rank=1. Accessed 17 February, 2023 | |
dc.identifier.citedreference | Bain SC, Mosenzon O, Arechavaleta R, et al. Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: rationale, design and patient baseline characteristics for the PIONEER 6 trial. Diabetes Obes Metab. 2019; 21: 499 - 508. | |
dc.identifier.citedreference | Gerstein HC, Colhoun HM, Dagenais GR, et al. Design and baseline characteristics of participants in the researching cardiovascular events with a weekly INcretin in diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. Diabetes Obes Metab. 2018; 20: 42 - 49. | |
dc.identifier.citedreference | Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020; 41: 255 - 323. | |
dc.identifier.citedreference | American Diabetes Association professional practice committee. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2022. Diabetes Care. 2022; 45: S125 - S143. | |
dc.identifier.citedreference | Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD). Diabetes Care. 2022; 45(11): 2753 - 2786. | |
dc.identifier.citedreference | Rawshani A, Rawshani A, Franzén S, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018; 379: 633 - 644. | |
dc.identifier.citedreference | American Diabetes Association professional practice committee. 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2022. Diabetes Care. 2022; 45: S144 - S174. | |
dc.identifier.citedreference | Marso SP, Kennedy KF, House JA, McGuire DK. The effect of intensive glucose control on all-cause and cardiovascular mortality, myocardial infarction and stroke in persons with type 2 diabetes mellitus: a systematic review and meta-analysis. Diab Vasc Dis Res. 2010; 7: 119 - 130. | |
dc.identifier.citedreference | Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021; 9: 653 - 662. | |
dc.working.doi | NO | en |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.